1. Apr 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
Randomized phase III trials are the gold standard of evidence-based drug development. They provide robust data on efficacy and safety and form the basis for regulatory decisions. However, with market approval, a new phase of evidence generation begins: the real-world...
17. Mar 2026 | Digital Health, General
AI in Everyday Health Care – Opportunities and Responsibility Artificial intelligence (AI) is being used by more and more patients, including in a health care context. Medical terms, findings, or information from doctor’s visits can be quickly looked up and explained....
4. Mar 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
What Insights Digital Real-World Data Provide and Where Their Limits Lie Digital therapy companions are increasingly being discussed in the pharmaceutical industry as a potential source of patient insights. At the same time, it often remains unclear what kind of...
17. Feb 2026 | General, Patient rights, Valuable information
IGeL: Between Freedom of Choice and Uncertainty You may have experienced this before: during a doctor’s visit, you are offered an additional examination or treatment that you have to pay for yourself – such as an ultrasound for early detection or a special laboratory...
4. Feb 2026 | B2B_Patient_Engagement
Rethinking Omnichannel Pharma Omnichannel strategies are firmly established in the pharmaceutical industry and primarily aim at consistent, personalized communication with physicians. Numerous professional publications describe omnichannel as a further development of...
